Mangalam Drugs and Organics Ltd

AI
Mangalam Drugs Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents
AI

Mangalam Drugs and Organics Ltd

₹ 30.4 -0.36%
21 Oct - close price
mangalamdrugs.com BSE: 532637 NSE: MANGALAM
About

Incorporated in 1977, Mangalam Drugs & Organics Ltd manufactures Active Pharmaceutical Ingredients and Intermediates.[1]

Key Points

Business Overview:[1]
MDOL (formerly Advent Pharma Pvt Ltd) is a part of the Mangalam group. The co manufactures bulk drugs, and organic and inorganic chemicals. It is among the few companies which are World Health Org.approved Indian companies to be associated
with the William J Clinton Foundation (Clinton Foundation) for manufacture of anti-malarial drugs. MDOL supplies artemisinin-based bulk drugs to pharmaceutical companies, for the manufacture of anti-malarial formulations.

Website BSE NSE
  • Market Cap ₹ 46.8 Cr.
  • Current Price ₹ 30.4
  • High / Low ₹ 73.0 / 22.7
  • Stock P/E
  • Book Value ₹ 65.3
  • Dividend Yield 0.00 %
  • ROCE -13.8 %
  • ROE -34.8 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Stock is trading at 0.47 times its book value

Cons

  • Company has low interest coverage ratio.
  • The company has delivered a poor sales growth of -9.39% over past five years.
  • Promoter holding is low: 35.6%
  • Company has a low return on equity of -11.0% over last 3 years.
  • Debtor days have increased from 45.3 to 63.4 days.
  • Promoter holding has decreased over last 3 years: -14.7%

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
87.46 81.56 97.34 102.24 76.53 79.94 88.71 72.78 57.21 49.54 58.38 67.29 57.12
90.94 79.37 90.36 90.54 68.34 71.25 79.94 62.88 61.86 52.37 59.96 72.65 56.22
Operating Profit -3.48 2.19 6.98 11.70 8.19 8.69 8.77 9.90 -4.65 -2.83 -1.58 -5.36 0.90
OPM % -3.98% 2.69% 7.17% 11.44% 10.70% 10.87% 9.89% 13.60% -8.13% -5.71% -2.71% -7.97% 1.58%
0.02 0.03 0.00 0.05 0.02 0.14 0.13 0.47 0.14 0.03 0.22 0.09 0.11
Interest 3.41 3.24 3.31 3.95 3.75 3.67 3.49 4.03 4.04 5.03 4.05 3.08 3.68
Depreciation 3.42 3.73 3.62 3.86 3.87 3.97 3.93 4.61 4.38 4.53 4.37 4.56 3.99
Profit before tax -10.29 -4.75 0.05 3.94 0.59 1.19 1.48 1.73 -12.93 -12.36 -9.78 -12.91 -6.66
Tax % -7.29% -25.05% -920.00% 9.90% -355.93% -125.21% 5.41% 90.75% 6.19% -41.42% 0.00% 1.16% 13.36%
-9.54 -3.56 0.50 3.55 2.68 2.69 1.40 0.15 -13.73 -7.25 -9.78 -13.06 -7.55
EPS in Rs -6.03 -2.25 0.32 2.24 1.69 1.70 0.88 0.09 -8.67 -4.58 -6.18 -8.25 -4.77
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
221 295 299 269 228 282 380 451 372 369 318 232 232
200 257 252 222 218 259 327 402 347 351 282 247 241
Operating Profit 20 38 47 47 10 24 53 49 26 17 36 -15 -9
OPM % 9% 13% 16% 17% 4.3% 8% 14% 11% 7% 4.7% 11% -6% -3.8%
0 0 -0 1 0 1 5 0 0 0 1 1 0
Interest 10 9 10 12 9 10 9 11 13 14 15 16 16
Depreciation 4 4 5 7 7 8 9 10 11 15 16 18 17
Profit before tax 6 24 31 29 -6 6 40 28 2 -11 5 -48 -42
Tax % -2% 33% 29% 32% 40% -32% 29% 29% 43% -18% -39% -9%
6 16 22 20 -8 8 28 20 1 -9 7 -44 -38
EPS in Rs 4.66 11.15 14.08 12.57 -5.07 5.21 17.67 12.42 0.80 -5.72 4.37 -27.68 -23.78
Dividend Payout % 0% 0% 0% 4% 0% 0% 0% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: -2%
5 Years: -9%
3 Years: -15%
TTM: -22%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: %
TTM: -297%
Stock Price CAGR
10 Years: -15%
5 Years: -26%
3 Years: -34%
1 Year: -57%
Return on Equity
10 Years: 4%
5 Years: -4%
3 Years: -11%
Last Year: -35%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 13 14 16 16 16 16 16 16 16 16 16 16
Reserves 16 47 70 88 80 88 115 135 136 127 133 87
78 60 66 69 65 52 70 88 89 107 96 113
63 38 38 54 50 75 64 90 117 108 114 92
Total Liabilities 170 160 190 227 211 231 264 328 358 357 359 308
53 54 93 102 103 101 118 135 142 147 156 148
CWIP 0 5 0 0 0 1 6 6 9 8 3 4
Investments 0 0 2 0 0 0 0 0 0 0 0 0
117 100 95 125 107 128 140 188 206 202 201 156
Total Assets 170 160 190 227 211 231 264 328 358 357 359 308

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
14 22 43 25 22 31 28 26 38 12 43 4
-4 -11 -39 -16 -9 -7 -31 -27 -22 -18 -19 -12
-10 -11 -3 -9 -11 -23 3 3 -17 6 -22 6
Net Cash Flow 1 -0 0 -0 1 0 -1 1 -1 -0 2 -2
Free Cash Flow 10 11 3 9 12 24 -4 -2 16 -6 23 -8
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 69% 68% 107% 66% 223% 129% 69% 70% 148% 71% 121% -30%

Ratios

Standalone / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 73 37 45 61 28 52 52 38 46 28 45 63
Inventory Days 134 85 69 132 175 121 85 139 200 185 303 239
Days Payable 128 37 38 82 77 106 63 65 139 124 199 160
Cash Conversion Cycle 79 85 75 111 126 67 74 112 107 88 148 142
Working Capital Days 26 32 19 31 21 10 23 43 38 18 13 -54
ROCE % 16% 29% 31% 25% 2% 11% 27% 18% 6% 1% 8% -14%

Insights

In beta
Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Export Turnover (Foreign Exchange Earned)
INR Lakhs

Log in to view insights

Please log in to see hidden values.

Login
Total Employees
Count
Anti-Malarial API Revenue Share
% of total revenue
Top Customer Concentration
% of total revenue
Total Production Volume
Metric Tons (MT)
R&D Scientists
Count
Installed Capacity
Tonnes Per Annum (TPA)
Tenofovir Disoproxil Fumarate Production
Metric Tons (MT)

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
50.31% 50.31% 50.31% 50.30% 50.30% 50.30% 50.30% 50.30% 35.64% 35.65% 35.65% 35.65%
0.10% 0.26% 0.21% 0.11% 0.11% 0.47% 0.53% 0.11% 0.13% 0.32% 0.11% 0.11%
49.59% 49.42% 49.47% 49.58% 49.58% 49.23% 49.16% 49.57% 64.22% 64.03% 64.24% 64.24%
No. of Shareholders 18,61019,17319,31219,50819,67919,69719,72819,88121,22725,14024,46523,991

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings

Concalls

  • Aug 2016
    Transcript
    AI Summary
    PPT
  • May 2016
    Transcript
    AI Summary
    PPT
  • Feb 2016
    Transcript
    AI Summary
    PPT